BioSpace News Archive

NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced upcoming presentations at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI), from June 22 – 26, 2018 in Anaheim, Ca.

The funds will be used to accelerate Nitrome’s biological studies on a new drug target for Parkinson’s disease.

EdTech Breakthrough recognizes outstanding educational technology products and companies

Osmosis, the rapidly growing health platform, sparks interest from Felicis Ventures, among others, to further disruption of the medical education industry

The study represents a milestone in the ongoing partnership between OnKure and the University of Colorado system, with the drug discovery and development company built around basic research from CU Boulder and the clinical trial taking place in partnership with CU Cancer Center on the Anschutz Medical Campus.

Varian will showcase and discuss its latest innovations in radiotherapy at the DEGRO 25 meeting in Münster, Germany, June 13-16.

BioInvent International AB announces the publication of the first data from two parallel Phase l/lla clinical trials of its lead product candidate BI-1206 as single agent and/or in combination with rituximab, currently being conducting in the UK and the US/EU respectively.

Alkermes plc announced the initiation of the monotherapy expansion stage of its ARTISTRY-1 clinical trial to evaluate the efficacy, safety and tolerability of ALKS 4230 in treating patients with renal cell carcinoma or melanoma.

IMV Inc. (Nasdaq:IMV; TSX:IMV), a clinical stage immuno-oncology corporation, today announced updated data from the ongoing investigator-sponsored SPiReL Phase 2 clinical trial assessing IMV’s lead candidate, DPX-Survivac, in combination with intermittent low dose cyclophosphamide and Merck’s checkpoint inhibitor Keytruda® (pembrolizumab).

Following the announcement of the acquisition of emapalumab and related assets, Sobi™ intends to carry out a reorganisation to increase the focus of research & development resources to support its two core therapeutic areas: Haematology and Immunology.